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Abstract
Background: Advances in technology and the scientific understanding of disease processes are presenting
new opportunities to improve health through individualized approaches to patient management referred
to as personalized medicine. Future health care strategies that deploy genomic technologies and molecular
therapies will bring opportunities to prevent, predict, and pre-empt disease processes but will be
dependent on knowledge management capabilities for health care providers that are not currently
available. A key cornerstone to the potential application of this knowledge will be effective use of
electronic health records. In particular, appropriate clinical use of genomic test results and molecularly-
targeted therapies present important challenges in patient management that can be effectively addressed
using electronic clinical decision support technologies.
Discussion: Approaches to shaping future health information needs for personalized medicine were
undertaken by a work group of the American Health Information Community. A needs assessment for
clinical decision support in electronic health record systems to support personalized medical practices was
conducted to guide health future development activities. Further, a suggested action plan was developed
for government, researchers and research institutions, developers of electronic information tools
(including clinical guidelines, and quality measures), and standards development organizations to meet the
needs for personalized approaches to medical practice. In this article, we focus these activities on
stakeholder organizations as an operational framework to help identify and coordinate needs and
opportunities for clinical decision support tools to enable personalized medicine.
Summary: This perspective addresses conceptual approaches that can be undertaken to develop and
apply clinical decision support in electronic health record systems to achieve personalized medical care. In
addition, to represent meaningful benefits to personalized decision-making, a comparison of current and
future applications of clinical decision support to enable individualized medical treatment plans is
presented. If clinical decision support tools are to impact outcomes in a clear and positive manner, their
development and deployment must therefore consider the needs of the providers, including specific
practice needs, information workflow, and practice environment.
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In the coming years, electronic health records (EHR) will
have increasingly important roles in the delivery of health
care, particularly in creating new opportunities to
improve quality and effectiveness. Among the most
important features offered by EHR are electronic exchange
and interoperability of patient health information; new
tools for carrying out some care delivery functions, like
drug prescribing; supporting providers in the delivery of
evidence-based care, including incorporation of evolving
practice guidelines into point-of-care accessible informa-
tion formats; measurement of quality in care delivery; and
widespread access to large networks of data for research
and quality purposes. While improvements in quality of
care involve all of these functions, it is particularly in the
area of clinical decision support (CDS) that EHR-based
technology is expected to improve delivery of care in a
continually evolving manner.
There will be an interdependent relationship between
CDS and personalized medicine in the effort to achieve
improvements in the quality of health care. CDS will help
health care providers cope with an increase in the number
of clinical decisions and acceleration of knowledge devel-
opment that would not be manageable without EHR sys-
tems. As medical knowledge increasingly steers toward
variability in treatments based on individual patient fac-
tors, including genomic-related clinical variables, the
need for CDS as a central part of care delivery will grow.
Thus, improving quality of care is expected to involve
increasing numbers of options for therapy, based on
increasingly detailed amounts of quantitative data and
knowledge, and resulting in increasing precision and
effectiveness of care for each patient. For the most part,
CDS tools today do not provide support for computing of
complex quantitative determinations such as risk assess-
ment, determination of combinatorial therapeutic inter-
ventions, and prediction of outcomes from interventions.
Improvements in CDS development will be essential to
achieving measurable advances in clinical outcomes in
scenarios where health care providers are faced with
increasing numbers of clinical variables.
Today, even as the basic foundation of EHR systems is
being laid, the pathways for CDS development are simul-
taneously being designed. This task is complex in itself,
and it is made even more complex by the need for CDS
design to anticipate and accommodate the expected
growth of differentiation in patient care - i.e., personal-
ized medicine. In this paper, we examine the potential
and current state of CDS development; we identify roles
for key stakeholders involved in the various elements of
CDS design and construction; and, we recommend steps
the various stakeholders can take at this stage to enable
the long term goal of CDS support for personalized med-
icine.
Discussion
Future Applications of Clinical Decision Support in 
Personalized Medicine
While there are many contexts for which the term 'person-
alized medicine' can be applied, we take a broad view of
its future applications. Personalized medicine is defined
as the delivery of health care in a manner that is informed
by each person's unique clinical information; genetic,
genomic, and other molecular/biological characteristics;
and environmental influences. The goals of personalize
medicine are to take advantage of a molecular under-
standing of disease, combined with other individual fac-
tors, to optimize preventive health care strategies while
people are still well or at the earliest stages of disease. [1]
In 2007, the American Health Information Community
(AHIC) established a work group to address standards
and interoperability specifications to enable EHR systems
to exchange and apply genomic information in medical
decision-making. CDS was among the four priority areas
targeted for workgroup activity in large part because of the
complexity that individualized patient care delivery
presents to health care providers' practices. [2] Through
detailed analysis of existing resources and testimony pro-
vided in public meetings, the workgroup found that there
is no systematic process to develop, disseminate, and
incorporate evidence-based practice information within
the clinical community. As a consequence, the findings
indicated that it may take years to develop and incorpo-
rate guidelines into daily clinical practice through elec-
tronic systems. The workgroup indicated the importance
of clarifying the needs and opportunities for integrating
CDS tools to address personalized medicine as EHR sys-
tems begin to offer decision support capabilities and
adoption of their use increases. Further, the workgroup
found it useful to align the needs with existing capabilities
by organizations or stakeholders in CDS development to
support personalized medicine practices.
The completion of the Human Genome Project, followed
by the development of a more manageable understanding
of the human genome in the Hap Map project and the
launch of genome-wide association studies (GWAS),
marked a great accomplishment and initiated a burst in
scientific discovery of the genetic underpinnings of com-
mon diseases. [3] This is the basis for many current efforts
to enhance preventive care strategies, improve diagnosis,
avoid adverse events, and inform appropriate selection
and dosing of drug therapies using diagnostic and predic-
tive molecular tests. The last two decades have also
brought a shift toward a large number of molecularly-tar-
geted therapies, advanced imaging tools, and cell- andPage 2 of 11
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meet specific characteristics of each patient's disease
course. Insights gained from this research now show that
genomic information is leading to meaningful sub-strati-
fication of a wide array of disease conditions that enables
prediction an individual's of risk for disease and the like-
lihood of an effective or unsafe response to therapy.
Realization of personalized medicine is dependent on the
ability to collect, disseminate, and process complex infor-
mation in the context of clinical care. The traditional par-
adigm of a provider reading current literature and
submitting adverse event reports cannot support this com-
plexity. It requires an EHR infrastructure to provide access
to key clinical data with CDS capabilities that provide the
right information, at the right time, at the point-of-care.
CDS tools have the potential to enable personalized
approaches to health care by providing health care provid-
ers, their staff, and patients with information and prefer-
ences specific to the individual, intelligently filtered and
combined at appropriate times, to enhance health and
health care. Primary methodologies for CDS include
information retrieval; evaluation of logical conditions;
probabilistic and data-driven classification or prediction;
heuristic modeling systems; calculations, algorithms, and
multi-step processes; and associative groupings of ele-
ments. [4] CDS encompasses, but is not limited to, com-
puterized alerts and reminders to providers; methods to
bring care into compliance with clinical guidelines; gener-
ation of order sets, patient data reports and summaries,
and documentation templates; advice to promote more
accurate and timely diagnoses; and tools that enhance
clinical workflow. [5] Although deployed inconsistently
in health care at present, CDS tools may support a variety
of processes to improve health care quality by engaging
the patient in the decision-making process. [6] These
resources may also increase providers' effectiveness by
enhancing their ability to use a greater array of informa-
tion to improve the quality of care, avoid adverse events,
provide actionable guidelines, and efficiently integrate
newly-discovered information into clinical practice,
thereby enabling informed patient-provider interactions
and facilitating predictable outcomes in health care strat-
egies. [7-9] CDS tools also enable application of perform-
ance measures to practice: that is, tools that can embed
evidence-based treatment guidelines can also help to
assess practice-based quality improvement programs and
measure clinical outcomes. For CDS tools being used to
integrate multiple clinical variables and genetic test
results, clinical supporting documentation for the deci-
sion options should be transparent to the user to ensure
that the scientific basis for the recommended actions are
suitable for the patient of interest.
In summary, CDS tools will likely become critical compo-
nents of personalized medicine paradigms, which rely on
EHR capabilities to assess a variety of data types, including
an individual's genetic/genomic data, within evidence-
based guidelines and practices. As the individualized
information is accumulated and the applications of tai-
lored treatment decisions expand, it is likely that provid-
ers and patients will need CDS tools to reap the benefits
from the information influx. When combined with the
provider's clinical judgment, these tools will complement
non-EHR-based data sources (e.g., reference datasets from
genomic databases, laboratory reference sets, and web-
portals) to offer an additional resource to assist with clin-
ical decision-making.
The following commonly occurring clinical scenarios
compare and contrast current and future applications of
information support to facilitate individualized decision-
making. In addition, these examples demonstrate the gaps
in capabilities and can serve as a springboard for recom-
mendations to close them. These scenarios represent the
current knowledge base and are reflective of the types of
genetically-based information used in decision-making
today.
Example 1. Application of viral genotyping in therapeutic decision-
making
Current state of antiretroviral treatment for human 
immunodeficiency virus (HIV) infection
Patient X commences antiretroviral treatment after
testing positive for HIV. His health care provider pre-
scribes a non-nucleoside reverse transcriptase inhibi-
tor (NNRTI) and concurrently orders a genotype
resistance test to identify HIV-reverse-transcriptase-
based mutations, as certain variants may decrease the
effectiveness of the prescribed inhibitor. However,
despite the identification of the K103N mutation in
the reverse transcriptase, which is broadly accepted to
confer definitive resistance, [10] the treatment course
is not altered. As a result, the patient does not achieve
full antiviral suppressive effect.
While it may seem difficult to imagine that a health care
provider would order a resistance panel and then seem-
ingly ignore its results, the scenario is more complex than
this simple analysis. As with many rapidly-advancing
fields, the consensus on genotype is constantly evolving,
as is the health care providers' understanding of and cur-
rency with this knowledge. In a recent study concerning
HIV genotypic resistance testing and antiretroviral pre-
scription practices in a group of experienced HIV health
care providers, researchers analyzed the frequency with
which patients were prescribed antiretroviral therapies
that were inconsistent with viral genotypic information.
[11] Among patients in this group, 18% continued to bePage 3 of 11
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be resistant to the prescribed medication. In nearly one-
third of these instances, prescribers reported that these
actions were due to "erroneous oversights," suggesting
that CDS capabilities such as electronic prescription (e-
prescription) software integrated with genotypic test
ordering (see below) and appropriate information for
interpretation of results could reduce the incidence of
such inappropriate action.
Future state of antiretroviral treatment for HIV
Patient Y commences antiretroviral treatment after
testing positive for HIV. Using e-prescription software
embedded within the EHR system, his health care pro-
vider prescribes an NNRTI and is concurrently
prompted to order a genotype resistance test to iden-
tify mutations that may decrease the NNRTI's effec-
tiveness; the order is added with a single click from the
alert screen. The results are returned, and the test iden-
tifies the K103N mutation in the reverse transcriptase.
The automated electronic patient record system cross-
references the test result with the current prescription,
notifies the provider about the patient's resistance to
the current medication, and suggests several alternate
NNRTIs that are not contraindicated by this genotypic
result. The tool provides the physician with an "infor-
mation button" in the EHR that provides information
that augments the decision to change medication. The
physician makes thus makes medication changes
(with the help of tools similar to the one that facili-
tated the test ordering), and the patient achieves the
desirable reduction in viral load.
Example 2. Augmenting health risk determination using CDS tools
Current state of estimating invasive breast cancer risk
Patient X has a family history of breast cancer and ini-
tiates a conversation with her provider to discuss risk
prediction and preventive strategies. The provider uti-
lizes a web-based tool or user-installed program on
her personal digital assistant device such as the
National Cancer Institute's Breast Cancer Risk Assess-
ment Tool [12] (based on the Gail Model Breast Can-
cer Reduction Tool) that estimates the patient's risk of
developing invasive breast cancer during the next 5-
year period and up to age 90 years (lifetime risk). This
risk assessment is based on family, medical, and repro-
ductive history that must be manually entered into the
tool. The patient and the provider discuss the results
generated by the tool, and each receives a printed copy
of the results.
Future state of estimating invasive breast cancer risk
An EHR contains standardized family health history,
medical history, laboratory results (including genomic
information from previous testing), and other clinical
information. In addition, the EHR has embedded risk-
prediction tools, which can utilize more complex
information sources and do not require re-entry of
data that are contained within the patient's medical
record. As the patient enters various life stages for
which risk factors are modified or updated, the risk
determination is actively revised and provided to the
patient and provider, along with personalized infor-
mation and guidance on interpreting and addressing
the information provided. For example, on her 35th
birthday, Patient Y receives notification that she
should schedule an appointment with her provider to
discuss risk prediction and other preventive strategies
for breast cancer. This notification is generated based
on recommendations from evidence-based practice
guidelines. However, when combining this with
patient-specific information in the EHR, the provider
can receive an automatically-generated message that
details the patient's updated risk assessment and spur
a discussion with the patient during a routine health
visit. Because of the automated information delivery
and the detailed information provided in an electronic
CDS environment, patients gain knowledge about
health risks while providers are offered information
(and potentially a greater range of complementary,
pertinent information) more efficiently.
As demonstrated above, CDS tools will enable health care
providers and patients to more efficiently and effectively
gather, interpret, process, and apply an increasing volume
of complex information needed for up-to-date, best-prac-
tice care. However, for CDS to be effective in managing
decisions often encountered in primary care, such as dia-
betes, heart disease, or mental illness, algorithms must
integrate an increasing array of variables to tailor an accu-
rate and useful risk probability assessment to a given
patient. In addition, mitigating factors such as co-morbid-
ities and non-mutation-based genomic changes occur
over time and may create additional considerations when
developing an intervention. When one considers that
multiple gene combinations may suggest different man-
agement paradigms for a given condition, the landscape
becomes quite complex.
Challenges to the Adoption and Use of CDS Tools
The impact of EHRs and related platforms (such as per-
sonal health records) on patient outcomes has been
inconsistent and difficult to quantify. [7] While individual
institutions have demonstrated that locally-developed
HIT systems can improve health care quality and effi-
ciency [13] and can improve care for some chronic ill-
nesses, [14] incorporating interoperable CDS resources
into widely-disseminated health IT platforms remains
challenging for several reasons. First, these resources must
recognize evolving technologies, such as genomic assays,Page 4 of 11
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BRCA (genes associated with hereditary breast cancer) sce-
nario reveals, the use of genetic and genomic tests, when
coupled with predictive risk assessments provided by fam-
ily health history information, offers tremendous poten-
tial to deliver timely, appropriate prevention and care.
However, it also adds complexity to the decision-making
process that will only increase as additional genomic
information becomes validated.
In addition, interoperable tools must be founded on an
agreed-upon baseline set of evidence-based best practices
that exclude ad-hoc, vendor-specific, or experiential rules.
Third, formal medical education typically provides mini-
mal training in applying genetic/genomic tests and data,
limiting many health care providers' abilities to interpret
this information. Furthermore, constraints and demands
of current clinical practice often discourage the conven-
ient acquisition of this knowledge. To appropriately inter-
pret results, the provider must seek information from
external sources, such as the laboratory performing the
tests, knowledge repositories, or genetic specialists. Cur-
rently, this process is inefficient, and the burden for
improved information-handling will increase, particu-
larly among primary care practices, as more genomic
information is integrated into the health care system. If
CDS tools are to impact outcomes in a clear and positive
manner, their development and deployment must there-
fore consider the needs of the provider, including specific
practice needs, information workflow, and practice envi-
ronment.
Compared to paper-based systems, interoperable CDS
resources offer the potential to transfer information more
rapidly and perhaps more reliably, however much work
remains to be done before these resources become stand-
ard practice. Wide deployment of CDS tools supporting
clinical medical decision making will be facilitated
through standardization (agreed-upon standards for the
rules and data fields that will enable the various electronic
resources to utilize various data types and resources) and
interoperability (the capability of an information system
to exchange data with other systems). Data from different
sources, including EHRs, claims databases, genomic data-
bases, and laboratory results files, are used in various
ways. Standards and interoperability enable information
in each of these resources to be related to each other, cre-
ating new knowledge from their integration. Currently,
this goal is hampered by the challenges of incorporating
proprietary technologies that have developed over time in
existing EHR systems with emerging applications and
capabilities. Even widely-used predictive algorithms, such
as the National Cancer Institute's Breast Cancer Risk
Assessment Tool [12] and the National Heart, Lung, and
Blood Institute's "Framingham" risk assessment tool for
coronary heart disease, [15] are not always associated with
EHRs. Likewise, acceptance of automatically-deployed
alerts in clinical practice is constrained by lack of informa-
tion regarding which interventions (such as diagnostic
tests, devices, and therapies) work in given situations,
how users react to CDS-deployed messages, and how
these tools affect outcomes. As a result, there is a growing
need to understand how to incorporate these tools into
clinical workflows to meet the needs of providers and
patients.
As CDS becomes incorporated into EHRs, additional
efforts are required, both in research and application,
before these tools can be optimized for personalized dis-
ease management at the point-of-care. Appropriate over-
sight can facilitate the integration process by promoting
interoperable standards, assisting in the development of
quality control metrics for information used in CDS tools,
and assessing the impact of the tools on outcomes and
performance measures. The recommendations discussed
in this paper offer a dialogue to create avenues that will
ultimately facilitate the adoption and use of CDS tools in
medicine.
Stakeholders' Roles in Supporting Individualized 
Approaches to Health Care
The pathway to use CDS in support of personalized med-
icine requires many integrated components to be devel-
oped in parallel with the emerging EHR foundation in
health care. Developing a health care system that opti-
mizes personalized prevention and treatment requires
engagement from many diverse stakeholders. Organizing
the work that needs to be done by stakeholder organiza-
tions is a helpful framework to consider the actors and
actions needed for the complete picture of personalized
medicine CDS systems to emerge. These include the con-
sumer/patient, molecular diagnostic (laboratory test or
device) developer, providers, payor, CDS developers, and
oversight and regulatory bodies, among many others.
An overview of the continuum of information flow from
evidence development through clinical application using
EHR technology is shown in Figure 1. Personalized medi-
cal practices will increasingly be based on scientific evi-
dence gained from population-based longitudinal studies
and clinical research studies such as randomized clinical
trials. These inputs provide the evidence that certain med-
ical technologies are recommended or shown to have ben-
efit under various clinical conditions. This becomes the
basis for algorithms or treatment recommendations that
are integrated into practice guidelines for many medical
conditions to be used in patient care encounters in two
major applications. First, key program inputs are created
for CDS tools and integrated into electronic knowledge
base that is used to support the rules used in making rec-Page 5 of 11
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decisions. Second, the guidelines are increasingly used in
formulating quality measures to improve compliance in
medical decision-making and further assessment of pro-
vider and institutional compliance with recommended
medical practices. EHR systems will provide the frame-
work for supporting the appropriate use of guidelines in
medical decision-making and a means for evaluating per-
formance based health outcomes relative to clinical care
quality measures. Ultimately, health care quality improve-
ment measures will integrate over time information from
EHRs and potentially personal health records in a feed-
back mechanism for guideline improvements. This frame-
work presents an operational view of the key steps in
information development needed for CDS to support per-
sonalized medical practice.
To address the information needs outlined in the frame-
work above, this section discusses the key steps and which
stakeholders will likely be best suited to address them. A
summary of recommendations for the various stakehold-
ers is provided in Table 1. Much of the required work to
achieve CDS to support individualized medical practice is
not fundamentally different from other applications.
However, there are key aspects needed to support individ-
ualized approaches.
Multi-Sector Collaborations
Integrating CDS tools into clinical practice will require
multi-layered policy interventions to overcome systemic
barriers and challenges currently facing personalized
medicine. [16,17] In 2005-06, the HHS Office of the
National Coordinator for Health Information Technology
(ONC), [18] in partnership with the Agency for Health-
care Research and Quality (AHRQ), supported the devel-
opment of a National CDS Roadmap. [5] Coordinated by
the American Medical Informatics Association, the Road-
map activity convened experts in informatics, software
engineering, and evidence development from industry,
academia, and Federal agencies to develop a national plan
of action for CDS. The Roadmap identified three essential
elements for achieving the promise of CDS in health care:
1) access to the best knowledge available; 2) widespread
adoption and effective use of CDS tools; and 3) continu-
ous improvement of knowledge and CDS methods. This
plan represents a multi-sector strategy to advance the
development and application of decision-support capa-
bilities to enable individualized patient management,
thereby bridging the gap between current and future
approaches to CDS.
Government
Numerous government agencies currently participate in
initiatives that support information needs for personal-
ized medical practices including the Department of
Health and Human Services' (HHS) Personalized Health
Care Initiative, [19,20] the AHRQ-sponsored information
resources developed by the U.S. Preventive Services Task
Force (USPSTF), [21] and the Centers for Disease Control
and Prevention's Evaluation of Genomic Applications in
Practice and Prevention (EGAPP) initiative. [22] Through
2008, federal health information technology activities
were coordinated through the American Health Informa-
tion Community (AHIC), [23] which was established in
2005 to harmonize standards and to improve interopera-
bility and networking applications that will accelerate the
adoption of EHR systems and, ultimately, enable the
development of a nationwide interoperable EHR infra-
structure. ONC provides support for the AHIC and coor-
dinates HHS activities. During 2007, several AHIC
Workgroups identified CDS capabilities as a timely and
important area of focus, and a CDS Ad Hoc Planning
Group developed formal recommendations (Table 1) to
accelerate the implementation of robust and workflow-
sensitive CDS interventions that will drive measurable
improvement in key health care outcomes. [24] A multi-
stakeholder CDS Collaboratory, co-sponsored by AHRQ,
the HHS Personalized Health Care Initiative, and ONC,
The role of CDS tools and electronic and personal health reco ds in the devel pment of clinical practice guidelines and quality measuresFigu e 1
The role of CDS tools and electronic and personal 
health records in the development of clinical practice 
guidelines and quality measures. (Solid lines indicate 
currently available information flow patterns, dotted line rep-
resents potential pathways for future data flow).Page 6 of 11
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This group will build upon an assessment of CDS-related
federal agency activities conducted in 2007 to leverage
collective efforts and knowledge to expedite development
and adoption of effective CDS capabilities.
Among the priorities to enhance CDS development for
future personalized medicine approaches is the establish-
ment of EHR standards for a minimum data set of key var-
iables. This minimum data set would include
demographic data, physical measures, family health his-
tory, medications, health risk factors, and other parame-
ters. CDS tools can then be built through rules and
algorithms deployed through EHR systems using data
supported from the patient's EHR. Other priorities
include establishing pathways for integrating require-
ments for quality measures and standards and certifica-
tion with the primary organizations responsible for them.
Researchers and Research Institutions
CDS resources will accelerate the integration of new
knowledge and technologies into health care practice.
Standards development can orient this information
towards appropriate end-users, but only if the needs and
the output of those users are well understood. As such, the
development of optimal CDS tools will require input
from basic, clinical, and outcomes researchers. As new
information that may personalize medical care emerges,
researchers should consider engaging with professional
societies and EHR vendors to understand the types of
information that will be necessary to integrate the new
tools into care. Many current clinical systems include
mechanisms to provide providers with relevant, trusted
information as they make clinical decisions. As new tools
are integrated, however, researchers should explore meth-
odologies to present tools to providers, assess patient-pro-
vider interfaces, evaluate the impact of electronic tools in
shared decision-making, and support innovative software
applications that integrate multiple variables such as test
results, medical history, medication history, patient pref-
erences, and family health history. Current research on
the use of CDS tools in quality improvement measures,
workflow, and shared decision-making practices should
continue. [25] For example, a new initiative sponsored by
AHRQ focuses on the development, adoption, implemen-
tation, and evaluation of best practices using CDS tools
integrated within EHR, [26] and integrated health care
delivery systems, such as the Geisinger Health System, are
developing and applying CDS tools that include patient
preference modules within their electronic health envi-
ronments. [27]
Developers of Electronic Information Tools
Developers of electronic information tools can advance
personalized medicine by creating tools to identify appro-
priate molecular diagnostic tests, provide additional back-
ground material or references, or produce a personalized
interpretation based on existing medical data at the point-
of-care. When setting priorities, vendors should build
tools to support medical decision-making, including
workflow integration for diagnostic test orders, integra-
tion of test results into confirmatory tests, intervention
options, and patient information resources. High-impact
areas needed for development include tools for detecting
potential adverse events, genetic assay support for treat-
ment selection, and reminder systems for risk detection,
disease screening, and prevention.
These tools may capitalize on established EHR technolo-
gies such as e-prescribing. For example, by augmenting
the information provided to pharmacies, the pharmacist
could become a resource providing assurances for patient
safety, minimizing adverse events, and improving health
outcomes. Recent initiatives advanced by the Centers for
Medicare and Medicaid Services are providing financial
incentives for e-prescribing, and recent legislative action is
providing a stimulus incentive to physicians to use this
technology. [28] Providing pharmacists with clinical data
attributes (e.g., allergy status, pharmacokinetic data, phar-
macogenomic results or interpretations) can facilitate
communication, verify proper dosing decisions, and
enhance consumer education. In addition, including CDS
in e-prescribing systems may improve the safety, quality,
efficiency, and cost-effectiveness of care [29] and permit
providers to leverage standard-of-care guidelines. Devel-
oping tools to augment personalized medical decisions
will help avoid adverse events and improve decision-mak-
ing on dose and therapy selection that can be informed by
genetic or other molecular diagnostic testing. As technol-
ogy improves and greater strides are taken toward use of
CDS to improve performance against patient-care quality
measures, similar incentives may be considered to acceler-
ate the use of computer-assisted decision-making. New
techniques and educational efforts will likely be needed to
help care providers to integrate use of CDS tools into
workflow and patient-management paradigms.
Organizations that Develop Clinical Practice Guidelines 
and Quality Measures
Evidence-based practice guidelines offer the health care
provider a general reference framework from which to
choose interventions to address a patient's health care
needs. However, no two patients are alike, and an individ-
ual's unique genomic/biological profile and personal
preferences may suggest appropriate treatment avenues
that differ from those applicable to other individuals who
manifest the same disease. Practice guidelines should
include patient-specific factors for disease management
when these considerations are supported by an evidence
base. Given the multi-factorial nature of chronic condi-Page 7 of 11
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Table 1: Supporting Individualized Health Care: Recommendations for Stakeholders
Stakeholder Recommendations
Government * Support development of a minimum data set of personal attributes that 
contribute to individualized care
* Set national priorities for health care quality improvement driven by 
the National Quality Forum
* Identify priorities for Federally-funded CDS efforts
* Evaluate the impact of these programs on high-priority areas by 
representatives of Federal agencies
* Work with HITSP [31] to identify standard data types needed to 
support CDS tools of high-priority conditions determined by national 
priority-setting efforts
* Coordinate with CCHIT [32] on certification criteria for CDS to 
enable support of personalized medical practices
* Expand research support to promote best practices for utilizing CDS 
tools in EHR systems
Researchers and Research Institutions * Engage professional societies and EHR vendors to understand the 
types of information necessary to integrate new CDS tools into health 
care
* Explore methodologies to present tools to providers
* Assess patient-provider interfaces
* Evaluate the role and impact of electronic tools in shared decision-
making
* Support innovative software applications that integrate multiple 
variables (e.g., test results, medical/medication history, patient 
preferences, family health history).
Developers of Electronic Information Tools * Create tools to identify appropriate molecular diagnostic tests, 
provide additional background material or references, or produce a 
personalized interpretation based on existing medical data at the point-
of-care
* Build tools to support workflow integration for diagnostic test orders, 
integration of test results into confirmatory tests, intervention options, 
and patient information resources.
Developers of Clinical Practice Guidelines (CPG) and Quality Measures 
(QM)
* Include patient-specific factors for disease management when 
supported by an evidence base (CPG)
* Incorporate differences among subsets of patients (CPG)
* Translate practice guidelines into machine-readable formats to 
integrate into CDS tools (CPG)
* Work with electronic tool developers to create standard data formats 
that can be used to structure guidelines for import and use in CDS 
formats (CPG)
* Work with professional societies to design measures that incorporate 
into EHRs (QM)
* Harmonize measure specifications with EHR standards and 
requirements (QM)
* Ensure that EHRs are equipped to capture dataset to evaluate quality 
measures (QM).
Developers of EHR Standards * Encourage standards development for integrating practice guidelines 
into CDS tools and with EHR systems
* Prioritize genetic test and family history application standards 
development and certification processes
* Foster development of evaluation criteria for the usability and 
effectiveness of CDS tools in EHR systems.
BMC Medical Informatics and Decision Making 2009, 9:44 http://www.biomedcentral.com/1472-6947/9/44tions commonly encountered in primary care (e.g., type 2
diabetes, cardiovascular diseases, dyslipidemias, depres-
sion), however, it is reasonable to expect increasingly
nuanced treatment algorithms to emerge. To benefit
patients fully, clinical practice guidelines and quality
measures must incorporate differences among subsets of
patients as the relationships between molecular profiles
and treatment response are elucidated. As mentioned pre-
viously, CDS tools have the potential to identify diagnos-
tic tests and other criteria to stratify patients and identify
the appropriate clinical guidelines for a given subset of
patients. In turn, these tools can inform quality improve-
ment efforts at the level of the practice and quality metrics
related to policy development and education. However,
practice guidelines must be translated into machine-read-
able formats to integrate into CDS tools, and it is recom-
mended that organizations that develop practice
guidelines work with electronic tool developers to create
standard data formats that can be used to structure guide-
lines so that they can be imported and used in CDS for-
mats.
Recent legislation, such as the Medicare Improvements for
Patients and Providers Act of 2008 [28] and American
Recovery and Reinvestment Act of 2009 [30], identifies
the need for a consensus-based processes to prioritize,
endorse, and maintain performance measures and use
them with EHR systems to provide meaningful improve-
ments in health care practices. As national priorities for
health care quality are established by quality alliances and
other health care stakeholders (e.g., consumers, purchas-
ers/employers, providers, accreditation programs, insur-
ers, governmental and other organizations), the effects of
individualized approaches on treatment decisions and
procedures must be considered. Based on potential chal-
lenges to incorporate individualized approaches to care
into clinical guidelines and quality measures, specialty
societies, health systems, and other groups with longitudi-
nal databases that develop clinical guidelines should har-
monize their guidelines and engage CDS tool developers.
These harmonized guidelines should leverage evidence
for stratifying patients with all types of biological differ-
ences and incorporate individualized approaches to clini-
cal care. In addition, EHRs and CDS tools may provide a
near real-time data stream for guideline developers and
clinical researchers to collect performance measurement
data and refine the evidence base, practice guidelines, and
procedural and quality measures. For example, standard-
ized exclusion lists within the EHR may provide data to
explain deviations from a guideline, such as contraindica-
tion because of genetic or other interaction or patient may
have opted out of treatment. Thus, developers of quality
measures are strongly encouraged to work with the vendor
community to design measures that incorporate into
EHRs, harmonize measure specifications with EHR stand-
ards and requirements, and ensure that EHRs are
equipped to capture dataset to evaluate quality measures.
Organizations that Develop Health Information 
Technology Standards
The broad integration of complex, personalized informa-
tion into the health care delivery process through CDS
tools will require the development of standards to permit
disparate entities (e.g., provider, clinical laboratory,
patient, payer, pharmacy, research community) to utilize
and exchange data. Considerations may include standard-
ized terminology, metrics, and guidelines; examination of
the workflow between various entities; identification of
special datasets to collect (such as for safety monitoring or
quality measures); and identification of policy and techni-
cal issues. EHR standards development organizations are
encouraged to consider standards for templates that ena-
ble the integration of best practices into EHR systems. In
addition, standards developers can recognize the value
and potential of coupling genetic and family history infor-
mation by prioritizing standards development through
the Health Information Technology Standards Panel [31]
and the Certification Council for Health Information
Technology (CCHIT). [32] Recently, CCHIT announced
plans to include CDS as an area of advanced technology
that will be undergoing accelerated steps toward EHR cer-
tification standards in 2009-10. Standards-development
organizations can also work to encourage evaluation
measures for usability testing and performance of CDS
tools in electronic information environments. These steps
will help define value for users and create incentives for
new tool development.
Summary
Science, technology, and medical practice continue to
enable innovative individualized approaches to health
care that require sophisticated reasoning and decision
making. The rate of development of these approaches will
only accelerate, dramatically expanding patients' and pro-
viders' needs for tools to help process this information
and take appropriate action. At present, electronic tools to
support this approach to health care are used infrequently
in EHR systems, yet these tools will be essential to support
future point-of-care decision-making. As CDS develop-
ment activities begin to unfold, assurances that these tech-
nologies will accommodate individualized approaches in
medical decision-making will be essential for achieving
more effective care through personalized medicine. Elec-
tronic information tool developers, researchers and
research institutions, and standards development organi-
zations will each have a role in bringing individualized
approaches to health care, thereby effecting a transition
that will benefit all health care stakeholders. It will require
the efforts of numerous individuals and teams to develop
the health care system that leverages individual differ-Page 9 of 11
(page number not for citation purposes)
BMC Medical Informatics and Decision Making 2009, 9:44 http://www.biomedcentral.com/1472-6947/9/44ences for the prevention, early detection, and tailored
treatment of human disease. Identifying key roles and
activities across the health care enterprise can help accel-
erate the achievement of this goal for the benefit of
patients and providers.
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